07.01.26 -- A Mid-Year Look At The 2026 Life Sciences Industry

Join Advancing RNA Live Chief Editor Anna Rose Welch and expert panelists on July 9 at 11 AM ET. for the live virtual event: The mRNA Therapeutics Regulatory Paradigm: A Closer Look. This discussion is free thanks to event sponsor Roche CustomBiotech. Can't join live? No problem. Register today and reserve your link for the On Demand connection.

RNAi therapeutics may help oncology move beyond single-target drugs by disrupting adaptive tumor survival networks driving resistance in solid tumors.

Can we actually achieve metric-ton siRNA production using enzymatic ligation? While the ligation step is highly scalable, upstream "blockmer" synthesis remains the primary bottleneck. Advancing RNA Live panelists Claire MacCleod and Jill Caswell discuss the shift from "scaling out" to "scaling up" and lessons learned in the process of achieving larger-scale production. 

In this two-part series, Gallagher shares more about her goals for Atrium following its spin-out from Novartis, articulating what it looks like and means to “pave a path” to greater patient access in rare cardiomyopathies. Here in part one, we start with a look into the formation of Atrium, sharing the “why” behind the company’s formation and what’s next for the company’s targeted delivery platform.